ACTAVIS PHARMA DEVELOPMENT CENTRE PVT LTD

Company Type: Development and Research Facility (supporting pharmaceutical manufacturing)

Introduction:

ACTAVIS PHARMA DEVELOPMENT CENTRE PVT LTD, located in India, is a specialized facility dedicated to pharmaceutical research and development. It operates as an integral part of the global pharmaceutical enterprise, specifically under Teva Pharmaceutical Industries Ltd., following Teva's acquisition of Actavis Generics.

This center is crucial for the innovation and advancement of pharmaceutical products, focusing on both generic and specialty medicines. Its core activities include formulation development, analytical method development and validation, process development, and comprehensive stability studies. The research and development conducted here directly supports the global manufacturing and market release of a diverse portfolio of pharmaceutical products.

Therefore, it is neither a factory for large-scale commercial production nor a trading company. Instead, it functions as a critical R&D hub, driving scientific progress and providing essential technical support for the manufacturing operations of its parent organization.

ACTAVIS PHARMA DEVELOPMENT CENTRE PVT LTD in India primarily produces the following within its research and development capacity:

1. Pharmaceutical formulations for various dosage forms, including tablets, capsules, injectables, and topical formulations.

2. Drug delivery systems.

3. Analytical methods for drug substance and drug product characterization.

4. Manufacturing processes for Active Pharmaceutical Ingredients (APIs) and finished pharmaceutical products.

5. Regulatory dossiers and documentation to support product approvals.

6. Clinical trial materials for human studies.

These developments contribute to the global product portfolio of its parent company, Teva Pharmaceutical Industries, which manufactures and sells a broad range of generic and specialty medicines across numerous therapeutic areas worldwide. The development center itself does not directly sell commercial finished pharmaceutical products to the market.